Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunoliposomes for cancer therapy.

Roland E Kontermann1

  • 1Institut für Zellbiologie und Immunologie, Universität Stuttgart, Allmandring 31, 70569 Stuttgart, Germany. roland.kontermann@izi.uni-stuttgart.de

Current Opinion in Molecular Therapeutics
|March 2, 2006
PubMed
Summary

Immunoliposomes enhance drug delivery by targeting cancer cells, improving therapeutic efficacy. Recent advancements show promise for targeted cancer therapies, with one formulation nearing preclinical studies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Comparison of Cost-Effective Sensors for a Fluorescence-Based Detection System Used in Biodiagnostic Devices.

Biosensors·2026
Same author

Novel bispecific T-cell engagers overcoming acquired EGFR resistance.

mAbs·2026
Same author

BCL-xL as a therapeutic target in cetuximab-refractory colorectal cancer.

Cell death & disease·2026
Same author

Oncolytic adenoviruses encoding bispecific T cell engagers or a novel trispecific T cell engager for dual-targeting of c-MET and EGFR.

Molecular therapy. Oncology·2026
Same author

The making of multispecific immunoglobulins - a clinical perspective.

mAbs·2026
Same author

Trispecific eFab-eIg T-cell engagers targeting HER2 and HER3.

Frontiers in immunology·2025

Area of Science:

  • Biotechnology
  • Nanomedicine
  • Pharmacology

Background:

  • Liposomes are advanced drug delivery systems protecting therapeutics and enhancing drug payload.
  • Current liposomal chemotherapy primarily relies on passive targeting mechanisms like enhanced permeability and retention (EPR).
  • Antibody-functionalized liposomes (immunoliposomes) offer potential for active, cell-specific drug delivery.

Purpose of the Study:

  • To review the advancements in liposome and antibody technology for drug delivery.
  • To highlight the progress in developing targeted immunoliposomes for cancer therapy.
  • To discuss the future prospects of immunoliposomal formulations in clinical applications.

Main Methods:

  • Review of recent scientific literature on liposome and antibody engineering.
  • Analysis of studies focusing on immunoliposome development and preclinical testing.
  • Examination of manufacturing processes for Good Manufacturing Practice (GMP)-compliant immunoliposomes.

Main Results:

  • Significant progress has been achieved in enhancing the efficacy of both liposomes and antibodies.
  • Immunoliposomes demonstrate improved targeting capabilities compared to conventional liposomes.
  • One immunoliposomal formulation is currently undergoing GMP manufacturing for preclinical evaluation.

Conclusions:

  • Immunoliposomes represent a significant advancement in targeted cancer drug delivery.
  • Continued research and development are expected to yield further immunoliposomal formulations.
  • The progression towards GMP-compliant manufacturing signifies the clinical potential of immunoliposomes.

Related Experiment Videos